Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development

References

• Gottlieb SL, Low N, Newman LM, et al. Toward global prevention of sexually transmitted infections (STIs): The need for STI vaccines. Vaccine. 2014;32(14):1527–1535.
   PubMed Web of Science ®Google Scholar
• Kumamoto Y, Iwasaki A. Unique features of antiviral immune system of the vaginal mucosa. Curr Opin Immunol. 2012;24(4):411–416.
   PubMed Web of Science ®Google Scholar
• Mayaud P, McCartney D, Mabey D. Hunter’s Tropical medicine and emerging infectious diseases. In: Sexually transmitted infections. Ryan ET, Hill DR, Endy TP, editors. Elsevier; 2020. p. 52–68.
   Google Scholar
• Misra A, Thippeshappa R, Kimata JT. Macaques as model hosts for studies of HIV-1 infection. Front Microbiol. 2013;4:176.
   PubMed Web of Science ®Google Scholar
• Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee pan troglodytes. Nature. 1999;397(6718):436–441.
   PubMed Web of Science ®Google Scholar
• Wertheim JO, Smith MD, Smith DM, et al. Evolutionary origins of human herpes simplex viruses 1 and 2. Mol Biol Evol. 2014;31(9):2356–2364.
   PubMed Web of Science ®Google Scholar
• Yang C, Ruan P, Ou C, et al. Chronic hepatitis B virus infection and occurrence of hepatocellular carcinoma in tree shrews (Tupaia belangeri chinensis). Virol J. 2015;12(1):26.
   PubMedGoogle Scholar
• Wieland SF. The chimpanzee model for hepatitis B virus infection. Cold Spring Harb Perspect Med. 2015;5(6):a021469.
   PubMed Web of Science ®Google Scholar
• Tang H, Oishi N, Kaneko S, et al. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci. 2006;97(10):977–983.
   PubMed Web of Science ®Google Scholar
• Faridi R, Zahra A, Khan K, et al. Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J. 2011;8(1):269.
   PubMedGoogle Scholar
• Rimsky L, Hauber J, Dukovich M, et al. Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature. 1988;335(6192):738–740.
   PubMed Web of Science ®Google Scholar
• Nicot C. Overview on HTLV-1 p12, p8, p30, p13: Accomplices in persistent infection and viral pathogenesis. Front Microbiol. 2012;3:400.
   PubMed Web of Science ®Google Scholar
• Kardani K, Hashemi A, Bolhassani A. Comparative analysis of two HIV-1 multiepitope polypeptides for stimulation of immune responses in BALB/c mice. Mol Immunol. 2020;119:106–122.
   PubMed Web of Science ®Google Scholar
• Kardani K, Hashemi A, Bolhassani A. Comparison of HIV-1 Vif and Vpu accessory proteins for delivery of polyepitope constructs harboring Nef, Gp160 and P24 using various cell penetrating peptides. PLoS One. 2019;14(10):e0223844.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Kardani K, Vahabpour R, et al. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses. Immunol Lett. 2015;168(2):366–373.
   PubMed Web of Science ®Google Scholar
• Dolan A, Jamieson FE, Cunningham C, et al. The genome sequence of herpes simplex virus type 2. J Virol. 1998;72(3):2010–2021.
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436(7053):933–938.
   PubMed Web of Science ®Google Scholar
• Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol. 2014;20(24):7644.
   PubMed Web of Science ®Google Scholar
• Kardani K, Bolhassani A. HPV proteins and their functions. HPV Infect. 2018;1:8.
   Google Scholar
• Liu MA. DNA vaccines: A review. J Intern Med. 2003;253(4):402–410.
   PubMed Web of Science ®Google Scholar
• Saroja CH, Lakshmi PK, Bhaskaran S. Recent trends in vaccine delivery systems: A review. Int J Pharm. 2011;1(2):64.
   Google Scholar
• Karimkhanilouyi S, Ghorbian S. Nucleic acid vaccines for hepatitis B and C virus. Infect Genet Evol. 2019;75:103968.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis. 2009;200(2):166–171.
   PubMed Web of Science ®Google Scholar
• Dai S, Wang H, Deng F. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. J Immunol Sci. 2018;2(2):36–41.
   Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: Passport to immune recognition. Methods. 2006;40(1):60–65.
   PubMed Web of Science ®Google Scholar
• Ober BT, Brühl P, Schmidt M, et al. Immunogenicity and safety of defective vaccinia virus lister: Comparison with modified vaccinia virus Ankara. J Virol. 2002;76(15):7713–7723.
   PubMed Web of Science ®Google Scholar
• Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel). 2014;2(3):624–641.
   PubMedGoogle Scholar
• Hanabuchi S, Ohashi T, Koya Y, et al. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity. J Natl Cancer Inst. 2001;93(23):1775–1783.
   PubMedGoogle Scholar
• Ando S, Hasegawa A, Murakami Y, et al. HTLV-1 Tax-specific CTL epitope-pulsed dendritic cell therapy reduces proviral load in infected rats with immune tolerance against Tax. J Immunol. 2017;198(3):1210–1219.
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol. 2005;79(1):410–418.
   PubMed Web of Science ®Google Scholar
• Brans R, Akhrameyeva NV, Yao F. Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J Invest Dermatol. 2009;129(10):2470–2479.
   PubMed Web of Science ®Google Scholar
• Prichard MN, Kaiwar R, Jackman WT, et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine. 2005;23(46–47):5424–5431.
   PubMed Web of Science ®Google Scholar
• Jin Y, Cao C, Li P, et al. Boosting immune response to hepatitis B DNA vaccine by coadministration of Prothymosin α-expressing plasmid. Clin Diagn Lab Immunol. 2005;12(12):1364–1369.
   PubMedGoogle Scholar
• Chen H, Wen B, Deng Y, et al. Enhanced effect of DNA immunization plus in vivo electroporation with a combination of hepatitis B virus core-PreS1 and S-PreS1 plasmids. Clin Vaccine Immunol. 2011;18(11):1789–1795.
   PubMedGoogle Scholar
• Villarreal DO, Wise MC, Siefert RJ, et al. Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity. Mol Ther. 2015;23(10):1653–1662.
   PubMed Web of Science ®Google Scholar
• Morello CS, Kraynyak KA, Levinson MS, et al. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine. 2012;30(46):6541–6550.
   PubMed Web of Science ®Google Scholar
• Namvar A, Bolhassani A, Javadi G, et al. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Sci Rep. 2019;9(1):1–22.
   PubMed Web of Science ®Google Scholar
• Johnson RP. Live attenuated AIDS vaccines: Hazards and hopes. Nat Med. 1999;5(2):154–155.
   PubMed Web of Science ®Google Scholar
• Li W, Joshi MD, Singhania S, et al. Peptide vaccine: Progress and challenges. Vaccines (Basel). 2014;2(3):515–536.
   PubMedGoogle Scholar
• Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Hum Vaccin Immunother. 2020;15:1–2.
   Google Scholar
• Jama NJ. A two-dose Hepatitis B vaccine for adults (heplisav-B). JAMA. 2018;319:822–823.
   PubMed Web of Science ®Google Scholar
• Christianson MS, Wodi P, Talaat K, et al. Primary ovarian insufficiency and human papilloma virus vaccines: A review of the current evidence. Am J Obstet Gynecol. 2020;222(3):239–244.
   PubMed Web of Science ®Google Scholar
• Eisinger RW, Erbelding E, Fauci AS. Refocusing research on sexually transmitted infections. J Infect Dis. 2019;jiz442. DOI:https://doi.org/10.1093/infdis/jiz442.
   Google Scholar
• Burm R, Collignon L, Mesalam AA, et al. Animal models to study hepatitis C virus infection. Front Immunol. 2018;9:1032.
   PubMed Web of Science ®Google Scholar
• Bubenik J. Animal models for development of therapeutic HPV16 vaccines (review).. Int J Oncol. 2002;20(1):207–212.
   PubMed Web of Science ®Google Scholar
• Desrosiers RC, Letvin NL. Animal models for acquired immunodeficiency syndrome. Rev Infect Dis. 1987;9(3):438–446.
   PubMedGoogle Scholar
• Kwant-Mitchell A, Ashkar AA, Rosenthal KL. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J Virol. 2009;83(20):10664–10676.
   PubMed Web of Science ®Google Scholar
• Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene. 2005;24(39):6005–6015.
   PubMed Web of Science ®Google Scholar
• Vercauteren K, de Jong YP, Meuleman P. Animal models for the study of HCV. Curr Opin Virol. 2015;13:67–74.
   PubMed Web of Science ®Google Scholar
• Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee pan troglodytes troglodytes. Nature. 1999;397(6718):436–441.
   PubMed Web of Science ®Google Scholar
• Buitrago-Pérez Á, Hachimi M, Dueñas M, et al. A humanized mouse model of HPV-associated pathology driven by E7 expression. PLoS One. 2012;7(7):e41743.
   PubMed Web of Science ®Google Scholar
• Guo WN, Zhu B, Ai L, et al. Animal models for the study of hepatitis B virus infection. Zool Res. 2018;39(1):25.
   PubMed Web of Science ®Google Scholar
• Vajdi A, Juher D, Saldaña J, et al. A multilayer temporal network model for StD spreading accounting for permanent and casual partners. Sci Rep. 2020;10(1):1–2.
   PubMed Web of Science ®Google Scholar
• Afonso PV, Cassar O, Gessain A. Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes. Retrovirology. 2019;16(1):39.
   PubMed Web of Science ®Google Scholar
• Futsch N, Mahieux R, Dutartre H. HTLV-1, the other pathogenic yet neglected human retrovirus: From transmission to therapeutic treatment. Viruses. 2018;10(1):1.
   Web of Science ®Google Scholar
• Chandra J, Woo WP, Dutton JL, et al. Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS One. 2019;14(12):e0226320.
   Web of Science ®Google Scholar
• Barnabas VR, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: New insights and interventions. Curr HIV Res. 2012;10(3):228–237.
   PubMed Web of Science ®Google Scholar
• Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824.
   PubMed Web of Science ®Google Scholar
• Nijmeijer BM, Koopsen J, Schinkel J, et al. Sexually transmitted hepatitis C virus infections: Current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc. 2019;22(S6):e25348.
   PubMedGoogle Scholar
• WHO. Global Hepatitis Report, 2017. Online at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/(2017).
   Google Scholar
• Pileggi C, Papadopoli R, Bianco A, et al. Hepatitis B vaccine and the need for a booster dose after primary vaccination. Vaccine. 2017;35(46):6302–6307.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Fact sheets. Hepatitis B. 18 July 2019.
   Google Scholar
• De Oliveira CM, Fregnani JH, Villa LL, et al. Updates and Highlights. Acta Cytol. 2019;63(2):159–168.
   PubMed Web of Science ®Google Scholar
• Wiyeh AB, Mome RK, Mahasha PW, et al. Effectiveness of the female condom in preventing HIV and sexually transmitted infections: A systematic review and meta-analysis. BMC Public Health. 2020;20(1):1–7.
   PubMed Web of Science ®Google Scholar
• Cox AL, El-Sayed MH, Kao JH, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17:533–542.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Wei JY, Wang L, et al. Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacol Sin. 2017;38(8):1093–1103.
   PubMed Web of Science ®Google Scholar
• Pilotti E, Bianchi V, De Maria A, et al. HTLV-1/-2 and HIV-1 co-infections: Retroviral interference on host immune status. Front Microbiol. 2013;4:372.
   PubMed Web of Science ®Google Scholar
• Chang CC, Crane M, Zhou J, et al. HIV and co-infections. Immunol Rev. 2013;254:114–142.
   PubMed Web of Science ®Google Scholar
• Sheth PM, Sunderji S, Shin LY, et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis. 2008;197(10):1394–1401.
   PubMed Web of Science ®Google Scholar
• Zheng YX, Ma SJ, Xiong YH, et al. The efficacy and safety of direct-acting antiviral regimens for HCV/HIV Co-infection: A systematic review and network meta-analysis. J Gastroenterol Hepatol. 2020. DOI:https://doi.org/10.1111/jgh.15051.
   Google Scholar
• Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus co-infection: Epidemiology, pathogenesis and treatment. AIDS. 2017;31(15):2035.
   PubMed Web of Science ®Google Scholar
• Okwen MP, Reid S, Njei B, et al. Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection. Cochrane Database Syst Rev. 2014;(10). doi:https://doi.org/10.1002/14651858.CD009886.pub2.
   Google Scholar
• Tumban E. A current update on human papillomavirus-associated head and neck cancers. Viruses. 2019;11(10):922.
   PubMed Web of Science ®Google Scholar
• Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci. 1980;77(12):7415–7419.
   PubMed Web of Science ®Google Scholar
• Quaresma JA, Yoshikawa GT, Koyama RV, et al. HTLV-1, immune response and autoimmunity. Viruses. 2016;8(1):5.
   Web of Science ®Google Scholar
• Martin JL, Maldonado JO, Mueller JD, et al. Molecular studies of HTLV-1 replication: An update. Viruses. 2016;8(2):31.
   Web of Science ®Google Scholar
• Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218(4572):571–573.
   PubMed Web of Science ®Google Scholar
• Tagaya Y, Matsuoka M, Gallo R. 40 years of the human T-cell leukemia virus: Past, present, and future. F1000Res. 2019;8:228.
   Google Scholar
• Einsiedel L, Spelman T, Goeman E, et al. Clinical associations of Human T-Lymphotropic Virus type 1 infection in an indigenous Australian population. PLoS Negl Trop Dis. 2014;8(1):e2643.
   PubMed Web of Science ®Google Scholar
• Soltani A, Hashemy SI, Avval FZ, et al. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomed Pharmacother. 2019;109:770–778.
   PubMed Web of Science ®Google Scholar
• Manel N, Kim FJ, Kinet S, et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell. 2003 Nov 14;115(4):449–459.
   PubMed Web of Science ®Google Scholar
• Jones KS, Petrow-Sadowski C, Bertolette DC, et al. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol. 2005;79(20):12692–12702.
   PubMed Web of Science ®Google Scholar
• Ghez D, Lepelletier Y, Lambert S, et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol. 2006;80(14):6844–6854.
   PubMed Web of Science ®Google Scholar
• Yoshimitsu M, Kozako T, Arima N. Prevention of human T-cell lymphotropic virus infection and adult T-cell leukemia. InT-Cell Leukemia-Characteristics, Treatment and Prevention. IntechOpen. 2013.
   Google Scholar
• Sugata K, Yasunaga JI, Mitobe Y, et al. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood. 2015;126(9):1095–1105.
   PubMed Web of Science ®Google Scholar
• Sundaram R, Sun Y, Walker CM, et al. A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A* 0201 transgenic mice: Implications for HTLV-1 vaccine design. Vaccine. 2003;21(21–22):2767–2781.
   PubMed Web of Science ®Google Scholar
• Mulherkar R, Karabudak A, Ginwala R, et al. In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection. Vaccine. 2018;36(33):5046–5057.
   PubMed Web of Science ®Google Scholar
• Kozako T, Fukada K, Hirata S, et al. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia. Mol Immunol. 2009;47(2–3):606–613.
   PubMed Web of Science ®Google Scholar
• Munson P, Liu Y, Bratt D, et al. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. Hum Vaccin Immunother. 2018;14(7):1820–1831.
   PubMed Web of Science ®Google Scholar
• Cui Z, Patel J, Tuzova M, et al. Strong T cell type-1 immune responses to HIV-1 Tat (1–72) protein-coated nanoparticles. Vaccine. 2004 Jun 30;22(20):2631–2640.
   PubMed Web of Science ®Google Scholar
• Kardani K, Bolhassani A, Agi E, et al. B1 protein: A novel cell penetrating protein for in vitro and in vivo delivery of HIV-1 multi-epitope DNA constructs. Biotechnol Lett. 2020;42(10):1847–1863.
   PubMed Web of Science ®Google Scholar
• Rostami B, Irani S, Bolhassani A, et al. Gene and protein delivery using four cell penetrating peptides for HIV-1 vaccine development. IUBMB Life. 2019;71(10):1619–1633.
   PubMed Web of Science ®Google Scholar
• Kadkhodayan S, Jafarzade BS, Sadat SM, et al. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model. Immunol Lett. 2017;188:38–45.
   PubMed Web of Science ®Google Scholar
• Abaitua F, Rodríguez JR, Garzón A, et al. Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res. 2006;116(1–2):11–20.
   PubMed Web of Science ®Google Scholar
• Brans R, Yao F. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol. 2010;10(1):163.
   PubMedGoogle Scholar
• Vagvala SP, Thebeau LG, Wilson SR, et al. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice. J Virol. 2009;83(2):953–960.
   PubMed Web of Science ®Google Scholar
• Awasthi S, Lubinski JM, Shaw CE, et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol. 2011;85(20):10472–10486.
   PubMed Web of Science ®Google Scholar
• Morello CS, Levinson MS, Kraynyak KA, et al. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol. 2011;85(7):3461–3472.
   PubMed Web of Science ®Google Scholar
• Halford WP, Püschel R, Gershburg E, et al. A live-attenuated HSV-2 ICP0-virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One. 2011;6(3):e17748.
   PubMed Web of Science ®Google Scholar
• Pishraft-Sabet L, Kosinska AD, Rafati S, et al. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96. Arch Virol. 2015;160(1):141–152.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Lü X, Lei YF, et al. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice. J Virol Methods. 2013;189(1):47–52.
   PubMed Web of Science ®Google Scholar
• Woo PC, Wong LP, Zheng BJ, et al. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine. 2001;19(20–22):2945–2954.
   PubMed Web of Science ®Google Scholar
• Kosinska AD, Zhang E, Johrden L, et al. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog. 2013;9(6):e1003391.
   PubMed Web of Science ®Google Scholar
• Gableh F, Saeidi M, Hemati S, et al. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci. 2016;23(1):16.
   PubMedGoogle Scholar
• Ahrends T, Bąbała N, Xiao Y, et al. CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination. Cancer Res. 2016;76(10):2921–2931.
   PubMed Web of Science ®Google Scholar
• Diniz MO, Sales NS, Silva JR, et al. Protection against HPV-16-associated tumors requires the activation of CD8+ effector memory T cells and the control of myeloid-derived suppressor cells. Mol Cancer Ther. 2016;15(8):1920–1930.
   PubMed Web of Science ®Google Scholar
• Allen A, Wang C, Caproni LJ, et al. Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. Cancer Immunol Immunother. 2018;67(4):627–638.
   PubMed Web of Science ®Google Scholar
• Talebi S, Bolhassani A, Sadat SM, et al. Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines. Biomed Pharmacother. 2017;85:148–154.
   PubMed Web of Science ®Google Scholar
• Mardani G, Bolhassani A, Agi E, et al. Protein vaccination with HPV16 E7/Pep-1 nanoparticles elicits a protective T-helper cell-mediated immune response. IUBMB Life. 2016;68(6):459–467.
   PubMed Web of Science ®Google Scholar
• Namvar A, Panahi HA, Agi E, et al. Development of HPV 16, 18, 31, 45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools. Biotechnol Lett. 2020;42(3):403–418.
   PubMedGoogle Scholar
• Shahbazi S, Bolhassani A. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines. Int Immunopharmacol. 2018;62:170–180.
   PubMed Web of Science ®Google Scholar
• Kabiri M, Sankian M, Hosseinpour M, et al. The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1. Int J Pharm. 2018;549(1–2):404–414.
   PubMedGoogle Scholar
• Kozako T, Hirata S, Shimizu Y, et al. Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant. Febs J. 2011;278(8):1358–1366.
   PubMed Web of Science ®Google Scholar
• Kazanji M, Heraud JM, Merien F, et al. Chimeric peptide vaccine composed of B-and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus). J Gen Virol. 2006;87(5):1331–1337.
   PubMedGoogle Scholar
• Frangione-Beebe M, Albrecht B, Dakappagari N, et al. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide. Vaccine. 2000;19(9–10):1068–1081.
   PubMed Web of Science ®Google Scholar
• Ohashi T, Hanabuchi S, Kato H, et al. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol. 2000;74(20):9610–9616.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Piepenbrink MS, Basu M, et al. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. Vaccine. 2019;37(17):2322–2330.
   PubMed Web of Science ®Google Scholar
• Billaut-Mulot O, Idziorek T, Ban E, et al. Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine. Vaccine. 2000;19(1):95–102.
   PubMed Web of Science ®Google Scholar
• Jones AT, Chamcha V, Kesavardhana S, et al. A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques. J Virol. 2018;92(5):e01796–17.
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Gómez CE, Sorzano CÓ, et al. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol. 2014;88(6):3392–3410.
   PubMed Web of Science ®Google Scholar
• Tohidi F, Sadat SM, Bolhassani A, et al. Induction of a robust humoral response using HIV-1 VLP MPER-V3 as a novel candidate vaccine in BALB/C mice. Curr HIV Res. 2019;17(1):33–41.
   PubMed Web of Science ®Google Scholar
• Wang K, Kappel JD, Canders C, et al. A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM. J Virol. 2012;86(23):12891–12902.
   PubMed Web of Science ®Google Scholar
• Petro C, Gonzalez PA, Cheshenko N, et al. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. Elife. 2015;4:e06054.
   Web of Science ®Google Scholar
• Shlapobersky M, Marshak JO, Dong L, et al. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol. 2012;93(6):1305.
   PubMedGoogle Scholar
• Frey SE, Houghton M, Coates S, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28(38):6367–6373.
   PubMed Web of Science ®Google Scholar
• Stamataki Z, Coates S, Abrignani S, et al. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis. 2011;204(5):811–813.
   PubMed Web of Science ®Google Scholar
• Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12(2):190–197.
   PubMed Web of Science ®Google Scholar
• Youn JW, Park SH, Lavillette D, et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology. 2005;42(6):1429–1436.
   PubMed Web of Science ®Google Scholar
• Lee H, Jeong M, Oh J, et al. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of hepatitis C virus infection. Sci Rep. 2017;7(1):43531.
   PubMed Web of Science ®Google Scholar
• Latimer B, Toporovski R, Yan J, et al. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Hum Vaccin Immunother. 2014;10(8):2357–2365.
   PubMed Web of Science ®Google Scholar
• Youn JW, Hu YW, Tricoche N, et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol. 2008;82(21):10896–10905.
   PubMed Web of Science ®Google Scholar
• Rollier CS, Paranhos-Baccala G, Verschoor EJ, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology. 2007;45(3):602–613.
   PubMed Web of Science ®Google Scholar
• Shirbaghaee Z, Bolhassani A, Mirshafiey A, et al. A Live Vector expressing HPV16 L1 generates an adjuvant-induced antibody response in vivo. Iran J Cancer Prev. 2015;8(6). DOI:https://doi.org/10.17795/ijcp-3991.
   Google Scholar
• Lisziewicz J, Bakare N, Calarota SA, et al. Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One. 2012;7(5):e35416.
   PubMed Web of Science ®Google Scholar
• Rodriguez B, Asmuth DM, Matining RM, et al. Safety, tolerability and immunogenicity of repeated doses of DermaVir, a candidate therapeutic HIV vaccine, in HIV infected patients receiving combination antiretroviral therapy: Results of the ACTG 5176 Trial. J Acquir Immune Defic Syndr. 2013;64(4):351–359.
   Web of Science ®Google Scholar
• Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68(7):4650–4655.
   PubMed Web of Science ®Google Scholar
• Sneller MC, Justement JS, Gittens KR, et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 2017;9(419):eaan8848.
   PubMed Web of Science ®Google Scholar
• Leal L, Guardo AC, Morón-López S, et al. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS. 2018;32(17):2533.
   PubMed Web of Science ®Google Scholar
• Pollard RB, Rockstroh JK, Pantaleo G, et al. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: A phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2014;14(4):291–300.
   PubMed Web of Science ®Google Scholar
• Brekke K, Sommerfelt M, Ökvist M, et al. The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study. BMC Infect Dis. 2017;17(1):228.
   PubMedGoogle Scholar
• Román VR, Jensen KJ, Jensen SS, et al. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: Safety, immunogenicity, and feasibility in Guinea-Bissau. AIDS Res Hum Retroviruses. 2013;29(11):1504–1512.
   PubMed Web of Science ®Google Scholar
• Karlsson I, Brandt L, Vinner L, et al. Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clin Immunol. 2013;146(2):120–130.
   PubMed Web of Science ®Google Scholar
• Boffito M, Fox J, Bowman C, et al. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial. Vaccine. 2013;31(48):5680–5686.
   PubMed Web of Science ®Google Scholar
• Tung FY, Tung JK, Pallikkuth S, et al. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy. Vaccine. 2016;34(19):2225–2232.
   PubMed Web of Science ®Google Scholar
• Hancock G, Morón-López S, Kopycinski J, et al. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA. HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc. 2017;20(1):21171.
   PubMedGoogle Scholar
• Iaria ML, Fiorentini S, Focà E, et al. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study. Vaccine. 2014;32(9):1072–1078.
   PubMed Web of Science ®Google Scholar
• Loret EP, Darque A, Jouve E, et al. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology. 2016;13(1):21.
   PubMedGoogle Scholar
• Goldstein G, Damiano E, Donikyan M, et al. HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia. Hum Vaccin Immunother. 2012;8(10):1425–1430.
   PubMed Web of Science ®Google Scholar
• Ensoli F, Cafaro A, Casabianca A, et al. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial. Retrovirology. 2015;12(1):33.
   PubMedGoogle Scholar
• Dinges W, Girard PM, Podzamczer D, et al. The F4/AS01B HIV-1 vaccine candidate is safe and immunogenic, but does not show viral efficacy in antiretroviral therapy-naive, HIV-1-infected adults: A randomized controlled trial. Medicine. 2016;95(6):e2673.
   PubMed Web of Science ®Google Scholar
• García F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013;5(166):166ra2.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Kwon DS, Macklin EA, et al. Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: Results of a randomized, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;71(3):246.
   PubMed Web of Science ®Google Scholar
• Macatangay BJ, Riddler SA, Wheeler ND, et al. Therapeutic vaccination with dendritic cells loaded with autologous HIV type 1-infected apoptotic cells. J Infect Dis. 2016;213(9):1400–1409.
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Routy JP, Welles S, et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;72(1):31.
   PubMed Web of Science ®Google Scholar
• De Bruyn G, Vargas-Cortez M, Warren T, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine. 2006;24(7):914–920.
   PubMed Web of Science ®Google Scholar
• Casanova G, Cancela R, Alonzo L, et al. A double-blind study of the efficacy and safety of the ICP10PK vaccine against recurrent genital HSV-2 infections. Cutis. 2002;70(4):205–206.
   PubMed Web of Science ®Google Scholar
• Wald A, Koelle DM, Fife K, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine. 2011;29(47):8520–8529.
   PubMed Web of Science ®Google Scholar
• Straus SE, Savarese B, Krause PR, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994;343(8911):1460–1463.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lajonchere L, Shoukry NH, Gra B, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat. 2009;16(3):156–167.
   PubMed Web of Science ®Google Scholar
• Yutani S, Komatsu N, Shichijo S, et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class IA alleles. Cancer Sci. 2009;100(10):1935–1942.
   PubMed Web of Science ®Google Scholar
• Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C non-responder patients with the peptide vaccine IC41. Gastroenterology. 2008;134(5):1385–1395.
   PubMed Web of Science ®Google Scholar
• Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology. 2003;38(5):1289–1296.
   PubMed Web of Science ®Google Scholar
• Habersetzer F, Baumert TF, Stoll-Keller F. Gl-5OO5, a yeast vector vaccine expressing an NS3-core fusion protein. Curr Opin Mol Ther. 2009;11(4):456–462.
   PubMedGoogle Scholar
• Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 2000;19(7–8):764–778.
   PubMed Web of Science ®Google Scholar
• Shih C, Chou SF, Yang CC, et al. Control and eradication strategies of hepatitis B virus. Trends Microbiol. 2016;24(9):739–749.
   PubMed Web of Science ®Google Scholar
• Yang SH, Lee CG, Park SH, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: A proof-of-concept study. Gene Ther. 2006;13(14):1110–1117.
   PubMed Web of Science ®Google Scholar
• Kim CY, Kang ES, Kim SB, et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med. 2008;40(6):669–676.
   PubMed Web of Science ®Google Scholar
• Lobaina Y, Michel ML. Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials. Vaccine. 2017;35(18):2308–2314.
   PubMed Web of Science ®Google Scholar
• Wilson EM, Tang L, Kottilil S. Eradication strategies for chronic hepatitis B infection. Clin Infect Dis. 2016;62(4):S318–S325.
   PubMedGoogle Scholar
• Seto WK, Fung J, Yuen MF, et al. Future prevention and treatment of chronic hepatitis B infection. J Clin Gastroenterol. 2012;46(9):725–734.
   PubMed Web of Science ®Google Scholar
• Lok AS, Pan CQ, Han SH, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65(3):509–516.
   PubMed Web of Science ®Google Scholar
• Xu DZ, Wang XY, Shen XL, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings. J Hepatol. 2013;59(3):450–456.
   PubMed Web of Science ®Google Scholar
• Heathcote J, McHutchison J, Lee S, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology. 1999;30(2):531–536.
   PubMed Web of Science ®Google Scholar
• Dembek C, Protzer U, Roggendorf M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol. 2018;30:58–67.
   PubMed Web of Science ®Google Scholar
• Rajčáni J, Szathmary S. Peptide vaccines: New trends for avoiding the autoimmune response. Open Infect Dis J. 2018;10(1):47–62.
   Google Scholar
• Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27(30):3883–3975.
   Web of Science ®Google Scholar
• Kawana K, Adachi K, Kojima S, et al. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine. 2014;32(47):6233–6239.
   PubMed Web of Science ®Google Scholar
• Frazer IH, Quinn M, Nicklin JL, et al. Phase I study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia. Vaccine. 2004;23(2):172–181.
   PubMed Web of Science ®Google Scholar
• Vici P, Pizzuti L, Mariani L, et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: Hope or reality from clinical studies. Expert Rev Vaccines. 2016;15(10):1327–1336.
   PubMed Web of Science ®Google Scholar
• Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther. 2004;15(5):421–431.
   PubMed Web of Science ®Google Scholar
• Y Carvajal AA, de la Garza A, Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma. BioDrugs. 2007;21(1):47–59.
   PubMed Web of Science ®Google Scholar
• van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 2012;61(9):1485–1492.
   PubMed Web of Science ®Google Scholar
• Zandberg DP, Rollins S, Goloubeva O, et al. A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother. 2015;64(3):367–379.
   PubMed Web of Science ®Google Scholar
• Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5(1):1–4.
   Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–2088.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Maes C, Clement F, et al. Randomized phase I: Safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS One. 2013;8(2):e55438.
   PubMed Web of Science ®Google Scholar
• Bekker LG, Moodie Z, Grunenberg N, et al. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: A phase 1/2 trial. Lancet HIV. 2018;5(7):e366–78.
   PubMed Web of Science ®Google Scholar
• Anderson J, Olafsdottir TA, Kratochvil S, et al. Molecular signatures of a TLR4 agonist-adjuvanted HIV-1 vaccine candidate in humans. Front Immunol. 2018;9:301.
   PubMed Web of Science ®Google Scholar
• Baden LR, Walsh SR, Seaman MS, et al. First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector. J Infect Dis. 2018;218(4):633–644.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018;392(10143):232–243.
   PubMed Web of Science ®Google Scholar
• Sacha JB, Chung C, Rakasz EG, et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol. 2007;178(5):2746–2754.
   PubMed Web of Science ®Google Scholar
• Stephenson KE, Keefer MC, Bunce CA, et al. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One. 2018;13(11):e0205139.
   Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. JAMA. 1999;282(4):331–340.
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D–adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652–1661.
   PubMed Web of Science ®Google Scholar
• Drane D, Maraskovsky E, Gibson R, et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers. Hum Vaccines. 2009;5(3):151–157.
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. vel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra1.
   PubMed Web of Science ®Google Scholar
• Kelly C, Swadling L, Capone S, et al. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology. 2016;63(5):1455–1470.
   PubMed Web of Science ®Google Scholar
• Elhanan E, Boaz M, Schwartz I, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018;22(1):151–158.
   PubMed Web of Science ®Google Scholar
• Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B®). Drugs. 2003;63(10):1021–1051.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–1466.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Brodszki N, Van Damme P, et al. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatr Infect Dis J. 2015;34(9):992–998.
   PubMed Web of Science ®Google Scholar
• Willems L, Hasegawa H, Accolla R, et al. Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Res. 2017;137:41–48.
   PubMed Web of Science ®Google Scholar
• Mahieux R. A vaccine against HTLV-1 HBZ makes sense. Blood Adv. 2015;126(9):1052–1053.
   Google Scholar
• Gutiérrez G, Rodríguez SM, De Brogniez A, et al. Vaccination against δ-retroviruses: The bovine leukemia virus paradigm. Viruses. 2014;6(6):2416–2427.
   PubMed Web of Science ®Google Scholar
• UNAIDS. 2018 Global AIDS Update: Miles to go-closing gaps, breaking barriers, righting injustices; available at: http://aidsinfo.unaids.org/.
   Google Scholar
• Sagar D, Masih S, Schell T, et al. In vivo immunogenicity of Tax (11-19) epitope in HLA-A2/DTR transgenic mice: Implication for dendritic cell-based anti-HTLV-1 vaccine. Vaccine. 2014;32(26):3274–3284.
   PubMed Web of Science ®Google Scholar
• Luciw PA. Human immunodeficiency viruses and their replication. In: Fields BN, editor. Virology. 3rd ed. Philadelphia: Lippincott-Raven; 1996. p. 1881–1952.
   Google Scholar
• Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med. 2009;15(8):871–872.
   PubMed Web of Science ®Google Scholar
• Teixeira C, Gomes JR, Gomes P, et al. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur J Med Chem. 2011;46(4):979–992.
   PubMed Web of Science ®Google Scholar
• Sanabani S, Neto WK, Kalmar EM, et al. Analysis of the near full length genomes of HIV-1 subtypes B, F and BF recombinant from a cohort of 14 patients in Sao Paulo, Brazil. Infect Genet Evol. 2006;6(5):368–377.
   PubMed Web of Science ®Google Scholar
• McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS. 2000;14(3):S31–S44.
   PubMed Web of Science ®Google Scholar
• Kirchhoff F. HIV life cycle: Overview. Encyclopedia of AIDS. 2013;1–9.
   Google Scholar
• Frankel AD, Young JA. HIV-1: Fifteen proteins and an RNA. Annu Rev Biochem. 1998;67(1):1–25.
   PubMedGoogle Scholar
• van Kooyk Y, Geijtenbeek TBDC. SIGN: Escape mechanism for pathogens. Nat Rev Immunol. 2003;3(9):697–709.
   PubMed Web of Science ®Google Scholar
• Dalgleish AG, Beverley PC, Clapham PR, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312(5996):763–767.
   PubMed Web of Science ®Google Scholar
• Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):667–673.
   PubMed Web of Science ®Google Scholar
• Freed EO, Martin MA. HIVs and their replication. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Field’s Virology. Lippincot: Williams & Wilkins; 2007.
   Google Scholar
• Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol. 2008;18(2):203–217.
   PubMed Web of Science ®Google Scholar
• Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med. 2004;10(12):1366–1373.
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101–105.
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25(3):373–381.
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol. 2005;23(1):307–335.
   PubMedGoogle Scholar
• Piguet V, Steinman RM. The interaction of HIV with dendritic cells: Outcomes and pathways. Trends Immunol. 2007;28(11):503–510.
   PubMed Web of Science ®Google Scholar
• Granelli-Piperno A, Pritsker A, Pack M, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol. 2005;175(7):4265–4273.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol. 1998;70: 83–243. Academic Press..
   PubMed Web of Science ®Google Scholar
• Alter G, Suscovich TJ, Teigen N, et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol. 2007;178(12):7658–7666.
   PubMed Web of Science ®Google Scholar
• Malleret B, Manéglier B, Karlsson I, et al. Primary infection with simian immunodeficiency virus: Plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood Adv. 2008;112(12):4598–4608.
   Google Scholar
• Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68(9):6103–6110.
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009;206(6):1253–1272.
   PubMed Web of Science ®Google Scholar
• Liao HX, Chen X, Munshaw S, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med. 2011;208(11):2237–2249.
   PubMed Web of Science ®Google Scholar
• Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008;82(24):12449–12463.
   PubMed Web of Science ®Google Scholar
• Gray ES, Moore PL, Choge IA, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol. 2007;81(12):6187–6196.
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat Rev Immunol. 2010;10(1):11–23.
   PubMed Web of Science ®Google Scholar
• Global HIV & AIDS statistics-2018 fact sheet: UNAIDS. 2018. Available from: https://www.unaids.org/en/resources/fact-sheet
   Google Scholar
• Adnan S, Reeves RK, Gillis J, et al. Persistent low-level replication of SIVΔnef drives maturation of antibody and CD8 T cell responses to induce protective immunity against vaginal SIV infection. PLoS Pathog. 2016;12(12):e1006104.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–1286.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220.
   PubMed Web of Science ®Google Scholar
• Lori F, Trocio J, Bakare N, et al. DermaVir, a novel HIV immunisation technology. Vaccine. 2005;23(17–18):2030–2034.
   PubMed Web of Science ®Google Scholar
• Morrow MP, Tebas P, Yan J, et al. Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015;23(3):591–601.
   PubMed Web of Science ®Google Scholar
• Dropulic LK, Oestreich MC, Pietz HL, et al. A randomized, double-blinded, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus (HSV) type 2 vaccine, HSV529, in adults with or without HSV infection. J Infect Dis. 2019;220(6):990–1000.
   PubMed Web of Science ®Google Scholar
• International AIDS vaccine Initiative. www.iavi.org
   Google Scholar
• Pitisuttithum P, Marovich MA. Prophylactic HIV vaccine: Vaccine regimens in clinical trials and potential challenges. Expert Rev Vaccines. 2020;19(2):133–142.
   PubMed Web of Science ®Google Scholar
• Baden LR, Karita E, Mutua G, et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: A randomized trial. Ann Intern Med. 2016;164(5):313–322.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer W. T cell-based strategies for HIV-1 vaccines. Hum Vaccin Immunother. 2020;16(3):713–722.
   PubMed Web of Science ®Google Scholar
• Sobieszczyk ME. Therapeutic HIV Vaccines and Broadly Neutralizing Antibodies. Top Antivir Med. 2020;27(4):97.
   PubMedGoogle Scholar
• Johnston C, Koelle DM, Wald A. Current status and prospects for development of an HSV vaccine. Vaccine. 2014;32(14):1553–1560.
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108(2):223–229.
   PubMed Web of Science ®Google Scholar
• Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine. 2016;34(26):2948–2952.
   PubMed Web of Science ®Google Scholar
• Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. J Infect Dis. 1998;178(6):1795–1798.
   PubMed Web of Science ®Google Scholar
• Lewis DA, Müller E, Steele L, et al. Prevalence and associations of genital ulcer and urethral pathogens in men presenting with genital ulcer syndrome to primary health care clinics in South Africa. Sex Transm Dis. 2012;39(11):880–885.
   PubMed Web of Science ®Google Scholar
• Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: Life cycle and development of inhibitors. Biochemistry (Moscow). 2014;79(13):1635–1652.
   PubMed Web of Science ®Google Scholar
• Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 2003;16(1):96–113.
   PubMed Web of Science ®Google Scholar
• Voellmy R, Bloom DC, Vilaboa N, et al. Recombinant Virus Vaccines. In: Development of recombinant HSV-based vaccine vectors. New York: Humana Press; 2017. p. 55–78.
   Google Scholar
• Dropulic LK, Cohen JI. The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines. 2012;11(12):1429–1440.
   PubMed Web of Science ®Google Scholar
• Coleman JL, Shukla D. Recent advances in vaccine development for herpes simplex virus types I and II. Hum Vaccin Immunother. 2013;9(4):729–735.
   PubMed Web of Science ®Google Scholar
• Cohen GH, Dietzschold B, De Leon MP, et al. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. J Virol. 1984;49(1):102–108.
   PubMed Web of Science ®Google Scholar
• Shukla D, Spear PG. Herpesviruses and heparan sulfate: An intimate relationship in aid of viral entry. J Clin Invest. 2001;108(4):503–510.
   PubMed Web of Science ®Google Scholar
• Ellermann-Eriksen S. Macrophages and cytokines in the early defence against herpes simplex virus. Virol J. 2005;2(1):59.
   PubMedGoogle Scholar
• Malmgaard L, Paludan SR, Mogensen SC, et al. Herpes simplex virus type 2 induces secretion of IL-12 by macrophages through a mechanism involving NF-κB. J Gen Virol. 2000;81(12):3011–3020.
   PubMedGoogle Scholar
• Kanangat S, Thomas J, Gangappa S, et al. Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. Implications in immunopathogenesis and protection. J Immunol. 1996;156(3):1110–1116.
   PubMed Web of Science ®Google Scholar
• Gomez M Efficacy against genital herpes infection using adjuvants with gD tripeptide liposomal vaccines or liposomal vaccines without gD tripeptide (Doctoral dissertation, California State Polytechnic University, Pomona) 2018.
   Google Scholar
• Kern AB, Schiff BL. Vaccine therapy in recurrent herpes simplex. Arch Dermatol. 1964;89(6):844–845.
   PubMedGoogle Scholar
• Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine. 1999;17(13–14):1681–1689.
   PubMed Web of Science ®Google Scholar
• Zhu XP, Muhammad ZS, Wang JG, et al. HSV-2 vaccine: Current status and insight into factors for developing an efficient vaccine. Viruses. 2014;6(2):371–390.
   PubMed Web of Science ®Google Scholar
• Johnston C, Koelle DM, Wald AHSV. 2: In pursuit of a vaccine. J Clin Invest. 2011;121(12):4600–4609.
   PubMed Web of Science ®Google Scholar
• Garnett GP, Dubin G, Slaoui M, et al. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect. 2004;80(1):24–29.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Cardin RD, Bravo FJ, et al. Successful application of prime and pull strategy for a therapeutic HSV vaccine. Npj Vaccines. 2019;4(1):1.
   PubMedGoogle Scholar
• Bernstein DI, Flechtner JB, McNeil LK, et al. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine. 2019;37(26):3443–3450.
   PubMed Web of Science ®Google Scholar
• Shi G, Suzuki T. Molecular basis of encapsidation of hepatitis C virus genome. Front Microbiol. 2018;9:396.
   PubMed Web of Science ®Google Scholar
• Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial. J Infect Dis. 1997;176(5):1129–1134.
   PubMed Web of Science ®Google Scholar
• Habersetzer F, Honnet G, Bain C, et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology. 2011;141(3):890–899.
   PubMed Web of Science ®Google Scholar
• Flechtner JB, Long D, Larson S, et al. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial. Vaccine. 2016;34(44):5314–5320.
   PubMed Web of Science ®Google Scholar
• Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3(1):1–9.
   Google Scholar
• Ogholikhan S, Schwarz KB. Hepatitis vaccines. Vaccines (Basel). 2016;4(1):6.
   Web of Science ®Google Scholar
• Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J. 2015;12(1):217.
   PubMedGoogle Scholar
• Basirnejad M, Bolhassani A, Sadat SM. The distinct role of small heat shock protein 20 on HCV NS3 expression in HEK-293T cell line. Avicenna J Med Biotechnol. 2018;10(3):152.
   PubMedGoogle Scholar
• Dustin LB, Bartolini B, Capobianchi MR, et al. Hepatitis C virus: Life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect. 2016;22(10):826–832.
   PubMed Web of Science ®Google Scholar
• Paul D, Madan V, Bartenschlager R. Hepatitis C virus RNA replication and assembly: Living on the fat of the land. Cell Host Microbe. 2014;16(5):569–579.
   PubMed Web of Science ®Google Scholar
• Verma R, Khanna P, Chawla S. Hepatitis C vaccine: Need of the hour. Hum Vaccin Immunother. 2014;10(7):1927–1929.
   PubMed Web of Science ®Google Scholar
• Alizadeh S, Irani S, Bolhassani A, et al. Simultaneous use of natural adjuvants and cell penetrating peptides improves HCV NS3 antigen-specific immune responses. Immunol Lett. 2019;212:70–80.
   PubMed Web of Science ®Google Scholar
• Didigu CA, Doms RW. Novel approaches to inhibit HIV entry. Viruses. 2012;4(2):309–324.
   PubMed Web of Science ®Google Scholar
• Man John Law L, Landi A, Magee WC, et al. Progress towards a hepatitis C virus vaccine. Emerg Microbes Infect. 2013;2(1):1–7.
   PubMed Web of Science ®Google Scholar
• Heim MH. Innate immunity and HCV. J Hepatol. 2013;58(3):564–574.
   PubMed Web of Science ®Google Scholar
• Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5(6):453–463.
   PubMed Web of Science ®Google Scholar
• Bartosch B, Vitelli A, Granier C, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 2003;278(43):41624–41630.
   PubMed Web of Science ®Google Scholar
• Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: Current status and remaining challenges. J Hepatol. 2008;49(4):625–633.
   PubMed Web of Science ®Google Scholar
• Kouka Saadeldin Abdelwahab ZN. Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol. 2016;22(2):862.
   PubMed Web of Science ®Google Scholar
• Kinchen VJ, Zahid MN, Flyak AI, et al. Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection. Cell Host Microbe. 2018;24(5):717–730.
   PubMed Web of Science ®Google Scholar
• Laidlaw SM, Dustin LB. An HCV vaccine on the fly. J Infect Dis. 2020;221(8):1216–1218.
   PubMed Web of Science ®Google Scholar
• Mirnurollahi SM, Bolhassani A, Irani S, et al. Expression and purification of HCV core and core-E1E2 proteins in different bacterial strains. Iran J Biotechnol. 2015;13(3):57.
   PubMed Web of Science ®Google Scholar
• Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res. 2014;105:100–111.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhong JY, Li JW. 117. Hepatitis C virus infection and vaccine development. J Clin Exp Hepatol. 2018;8(2):195–204.
   PubMed Web of Science ®Google Scholar
• Yan Y, Wang X, Lou P, et al. A nanoparticle-based HCV vaccine with enhanced potency. J Infect Dis. 2020;221(8): 1304–1314.
   PubMed Web of Science ®Google Scholar
• Christiansen D, Earnest-Silveira L, Grubor-Bauk B, et al. Preclinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep. 2019;9(1):1–3.
   PubMedGoogle Scholar
• Kardani K, Bolhassani A, Shahbazi S. 120. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine. 2016;34(4):413–423.
   PubMed Web of Science ®Google Scholar
• Walker CM. Designing an HCV vaccine: A unique convergence of prevention and therapy? Curr Opinion Virol. 2017;23:113–119.
   PubMed Web of Science ®Google Scholar
• Pestka JM, Zeisel MB, Bläser E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci. 2007;104(14):6025–6030.
   PubMed Web of Science ®Google Scholar
• Shoukry NH. Hepatitis C vaccines, antibodies, and T cells. Front Immunol. 2018;9:1480.
   PubMed Web of Science ®Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: Advances in hepatitis C virus vaccine formulations and modalities. ‎Expert Opin Ther Pat. 2012;22(4):391–415.
   PubMed Web of Science ®Google Scholar
• Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci. 2002 Nov 26;99(24):15661–15668.
   PubMed Web of Science ®Google Scholar
• Beaumont E, Roingeard P. Prospects for prophylactic hepatitis C vaccines based on virus-like particles. Hum Vaccin Immunother. 2013;9(5):1112–1118.
   PubMed Web of Science ®Google Scholar
• Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med. 2013;19(7):869.
   PubMed Web of Science ®Google Scholar
• Bailey JR, Barnes E, Cox AL. Approaches, progress, and challenges to hepatitis C vaccine development. Gastroenterology. 2019;156(2):418–430.
   PubMed Web of Science ®Google Scholar
• Christiansen D, Earnest-Silveira L, Chua B, et al. Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. Sci Rep. 2018;8(1):1–3.
   PubMedGoogle Scholar
• O’Hagan DT, Singh M, Dong C, et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine. 2004;23(5):672–680.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Javanzad S, Saleh T, et al. Polymeric nanoparticles: Potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother. 2014;10(2):321–332.
   PubMed Web of Science ®Google Scholar
• Amador-Cañizares Y, Martínez-Donato G, Álvarez-Lajonchere L, et al. HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin. World J Gastroenterol. 2014;20(1):148.
   PubMed Web of Science ®Google Scholar
• Sallberg MM, Frelin L, Diepolder H, et al. A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. J Hepatol. 2009;50:S18–S19.
   Web of Science ®Google Scholar
• Castellanos M, Cinza Z, Dorta Z, et al. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J Gene Med. 2010;12(1):107–116.
   PubMed Web of Science ®Google Scholar
• Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273–1285.
   PubMed Web of Science ®Google Scholar
• Basirnejad M, Bolhassani A. Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant. Protein Pept Lett. 2018 Oct 1;25(10):924–932.
   PubMed Web of Science ®Google Scholar
• Khan KH. DNA vaccines: Roles against diseases. Germs. 2013;3(1):26.
   PubMedGoogle Scholar
• Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis. 2012;55(suppl_1):S25–32.
   PubMedGoogle Scholar
• Bastani MN, Keyvani H, Esghaei M, et al. Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol. 2016;161(7):1899–1906.
   PubMed Web of Science ®Google Scholar
• Castillo I, Pardo M, Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004;189(1):7–14.
   PubMed Web of Science ®Google Scholar
• Castillo I, Rodriguez-Inigo E, Bartolome J, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut. 2005;54(5):682–685.
   PubMed Web of Science ®Google Scholar
• Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, et al. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis. 2006;43(10):1277–1283.
   PubMed Web of Science ®Google Scholar
• Yousif MM, Elsadek Fakhr A, Morad EA, et al. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents. Infez Med. 2018;26(3):237–243.
   PubMedGoogle Scholar
• Castillo I, Bartolomé J, Quiroga JA, et al. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol. 2010;82(9):1554–1559.
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350(11):1118–1129.
   PubMed Web of Science ®Google Scholar
• Shaheen S, Nouroz F, Khan S, et al. A review on hepatitis B virus, its genotypes and risk factors. Middle East J Sci Res. 2015;23(6):1152–1157.
   Google Scholar
• Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet. 1993;342(8883):1335–1340.
   PubMed Web of Science ®Google Scholar
• Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970;295(7649):695–698.
   Google Scholar
• Tang LS, Covert E, Wilson E, et al. Chronic hepatitis B infection: A review. JAMA. 2018;319(17):1802–1813.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–2063.
   PubMed Web of Science ®Google Scholar
• Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986;47(3):451–460.
   PubMed Web of Science ®Google Scholar
• Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007;13(1):48.
   PubMed Web of Science ®Google Scholar
• Lim SG, Agcaoili J, De Souza NN, et al. Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis. J Viral Hepat. 2019;26(7):803–817.
   PubMed Web of Science ®Google Scholar
• Ghasemi F, Rostami S, Ghayour-Mobarhan M, et al. Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection. Iran J Basic Med Sci. 2016;19(7):692.
   PubMed Web of Science ®Google Scholar
• Isogawa M, Robek MD, Furuichi Y, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005;79(11):7269–7272.
   PubMed Web of Science ®Google Scholar
• Wu J, Lu M, Meng Z, et al. Toll‐like receptor‐mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007;46(6):1769–1778.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Gehring AJ, Heitman J. Immune therapeutic strategies in chronic hepatitis B virus infection: Virus or inflammation control? PLoS Pathog. 2013;9(12):e1003784.
   Web of Science ®Google Scholar
• Thimme R, Wieland S, Steiger C, et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68–76.
   PubMed Web of Science ®Google Scholar
• Spellman M, Martin JT. Treatment of chronic hepatitis B infection with DV-601: A therapeutic vaccine. J Hepatol. 2011;54:S302.
   Google Scholar
• Stross L, Günther J, Gasteiger G, et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology. 2012;56(3):873–883.
   PubMed Web of Science ®Google Scholar
• Wu SF, Wang WJ, Gao YQ. Natural killer cells in hepatitis B virus infection. Braz J Infect Dis. 2015;19(4):417–425.
   PubMed Web of Science ®Google Scholar
• Maini MK, Peppa D. NK cells: A double-edged sword in chronic hepatitis B virus infection. Front Immunol. 2013;4:57.
   PubMed Web of Science ®Google Scholar
• Cassidy A, Mossman S, Olivieri A, et al. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines. 2011;10(12):1709–1715.
   PubMed Web of Science ®Google Scholar
• André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989;87(3):S14–S20.
   Google Scholar
• Krawczyk A, Ludwig C, Jochum C, et al. Induction of a robust T-and B-cell immune response in non-and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine. 2014;32(39):5077–5082.
   PubMed Web of Science ®Google Scholar
• Soulie JC, Devillier P, Santarelli J, et al. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Vaccine. 1991;9(8):545–548.
   PubMed Web of Science ®Google Scholar
• Chien YC, Jan CF, Kuo HS, et al. Nationwide hepatitis B vaccination program in Taiwan: Effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28(1):126–135.
   PubMedGoogle Scholar
• Monie A, Hung CF, Roden R, et al. Cervarix™: A vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics. 2008;2(1):107.
   Google Scholar
• Rey D, Piroth L, Wendling MJ, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): A multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15(11):1283–1291.
   PubMed Web of Science ®Google Scholar
• Mouchet J, Salvo F, Raschi E, et al. Hepatitis B vaccination and the putative risk of central demyelinating diseases–A systematic review and meta-analysis. Vaccine. 2018;36(12):1548–1555.
   PubMed Web of Science ®Google Scholar
• Lim SG. Heplisav™: A new hepatitis B vaccine. Future Med. 2008;3(2):109–117.
   Google Scholar
• Michel ML, Loirat D. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology. 2001;44(2–3):78–87.
   PubMed Web of Science ®Google Scholar
• Shahmoradi S, Yahyapour Y, Mahmoodi M, et al. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol. 2012;57(3):515–521.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yano K, Nozaki Y, et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatric Res. 1992;32(3):264–268.
   PubMed Web of Science ®Google Scholar
• Stanley M. Tumour virus vaccines: Hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160268.
   PubMed Web of Science ®Google Scholar
• Batdelger D, Dandii D, Jirathitikal V, et al. Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett Drug Des Discov. 2007;4(8):540–544.
   Web of Science ®Google Scholar
• Ponde RAA. Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity. Arch Virol. 2019;164(11):2645–2658.
   PubMed Web of Science ®Google Scholar
• Li J, Bao M, Ge J, et al. Research progress of therapeutic vaccines for treating chronic hepatitis B. Hum Vaccin Immunother. 2017;13(5):986–997.
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang X, Wang B, et al. Vaccine therapies for chronic hepatitis B: Can we go further? Front Med. 2014;8(1):17–23.
   PubMed Web of Science ®Google Scholar
• Almeida S, Borges O M. Nasal vaccines against hepatitis B: An update. Curr Pharm Biotechnol. 2015;16(10):882–890.
   PubMed Web of Science ®Google Scholar
• Kosinska AD, Liu J, Lu M, et al. Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: Preclinical studies in the woodchuck. Med Microbiol Immunol. 2015;204(1):103–114.
   PubMed Web of Science ®Google Scholar
• Kosinska AD, Bauer T, Protzer U. Therapeutic vaccination for chronic hepatitis B. Curr Opin Virol. 2017;23:75–81.
   PubMed Web of Science ®Google Scholar
• Fontaine H, Kahi S, Chazallon C, et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: A randomised trial-ANRS HB02 VAC-ADN. Gut. 2015;64(1):139–147.
   PubMed Web of Science ®Google Scholar
• Godon O, Fontaine H, Kahi S, et al. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther. 2014;22(3):675–684.
   PubMed Web of Science ®Google Scholar
• Yoon SK, Seo YB, Im SJ, et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int. 2015;35(3):805–815.
   PubMed Web of Science ®Google Scholar
• Protzer U, Maini MK, Knolle PA. Living in the liver: Hepatic infections. Nat Rev Immunol. 2012;12(3):201–213.
   PubMed Web of Science ®Google Scholar
• Akbar SM, Al-Mahtab M, Khan SI, et al. Current trends in hepatitis B vaccination. Future Virol. 2016;11(5):369–378.
   Web of Science ®Google Scholar
• Han IK, Kim YB, Kang HS, et al. Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods. 2006;38(2):106–111.
   PubMed Web of Science ®Google Scholar
• El-Maksoud MA, Habeeb MR, Ghazy HF, et al. Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2019;31(6):716–722.
   PubMed Web of Science ®Google Scholar
• Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepatitis. 2002;9(4):243–257.
   PubMed Web of Science ®Google Scholar
• Yip TC, Wong GL. Current knowledge of occult hepatitis B infection and clinical implications. Semin Liver Dis. 2019;39(2):249–260.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol. 2007;46(1):160–170.
   PubMed Web of Science ®Google Scholar
• Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol. 2014;20(20):5951.
   PubMed Web of Science ®Google Scholar
• Chang JJ, Mohtashemi N, Bhattacharya D. Significance and management of isolated hepatitis B core antibody (anti-HBc) in HIV and HCV: Strategies in the DAA era. Curr HIV/AIDS Rep. 2018;15(2):172–181.
   PubMed Web of Science ®Google Scholar
• Lok AS, Everhart JE, Di Bisceglie AM, et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54(2):434–442.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Inigo E, Bartolome J, Ortiz-Movilla N, et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol. 2005;79(24):15578–15581.
   PubMed Web of Science ®Google Scholar
• Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003;278(1):591–607.
   PubMed Web of Science ®Google Scholar
• Mphahlele MJ, Lukhwareni A, Burnett RJ, et al. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol. 2006;35(1):14–20.
   PubMed Web of Science ®Google Scholar
• Wang T, Shen C, Chen L, et al. Association of human leukocyte antigen polymorphisms with occult hepatitis B virus infection in a Shaanxi Han population. J Gen Med. 2017;19(9–10):e2987.
   Web of Science ®Google Scholar
• Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDs. 2006;20(9):1253–1260.
   PubMed Web of Science ®Google Scholar
• Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol. 2018;47:59–72.
   PubMed Web of Science ®Google Scholar
• Cohen J, HIV EM. Nobel prize in physiology or medicine: HIV, HPV researchers honored, but one scientist is left out. Science. 2008;322(5899):174–175.
   PubMed Web of Science ®Google Scholar
• Kardani K, Bolhassani A. General Description of HPVs. HPV Infect. 2018;1:1.
   Google Scholar
• Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):500–e1.
   PubMed Web of Science ®Google Scholar
• Kardani K, Naderi N, Bolhassani A. The life cycle and transmission of HPV types. HPV Infect. 2018;1:44.
   Google Scholar
• Moscicki AB, Schiffman M, Kjaer S, et al. Updating the natural history of HPV and anogenital cancer. Chapter 5 Vaccine. 2006;24(3):S42–S51.
   Google Scholar
• Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the riskof head and neck cancers: A pooled analysis in the international head and neck cancer epidemiology (INHANCE) consortium. Int J Epidemiol. 2010;39(1):166–181.
   PubMed Web of Science ®Google Scholar
• Burchell AN, Coutlée F, Tellier PP, et al. Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis. 2011;204(11):1723–1729.
   PubMed Web of Science ®Google Scholar
• Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: A modelling study. Lancet Public Health. 2019;4(1):e19–e27.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350.
   PubMed Web of Science ®Google Scholar
• Yang R, Yutzy WH, Viscidi RP, et al. Interaction of L2 with β-actin directs intracellular transport of papillomavirus and infection. J Biol Chem. 2003;278(14):12546–122553.
   PubMed Web of Science ®Google Scholar
• Yang R, Day PM, Yutzy WH, et al. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol. 2003;77(6):3531–3541.
   PubMed Web of Science ®Google Scholar
• Kines RC, Thompson CD, Lowy DR, et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci. 2009;106(48):20458–20463.
   PubMed Web of Science ®Google Scholar
• Richards RM, Lowy DR, Schiller JT, et al. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci. 2006;103(5):1522–1527.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911–1919.
   PubMed Web of Science ®Google Scholar
• Wang JW, Jagu S, Wu WH, et al. Seroepidemiology of human papillomavirus 16 (HPV16) L2 and generation of L2-specific human chimeric monoclonal antibodies. Clin Vaccine Immunol. 2015;22(7):806–816.
   PubMed Web of Science ®Google Scholar
• Kawana K, Matsumoto K, Yoshikawa H, et al. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology. 1998;245(2):353–359.
   PubMed Web of Science ®Google Scholar
• Roden RB, Yutzy WH, Fallon R, et al. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000;270(2):254–266.
   PubMed Web of Science ®Google Scholar
• Kardas-Nelson M. Vaccine uptake and prevalence of HPV related cancers in US men. BMJ. 2019;364:1210.
   Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–411.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–1585.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–580.
   PubMed Web of Science ®Google Scholar
• Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. J Immunol. 2014;192(9):4007–4011.
   PubMed Web of Science ®Google Scholar
• Dilley S, Miller KM, Huh WK. Human papillomavirus vaccination: Ongoing challenges and future directions. J Gynecol. 2020;156(2):498–502.
   PubMed Web of Science ®Google Scholar
• Clark KT, Trimble CL. Current status of therapeutic HPV vaccines. Gynecol Oncol. 2020;156(2):503–510.
   PubMed Web of Science ®Google Scholar
• Moreira ED, Block SL, Ferris D, et al. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138(2):e20154387.
   PubMed Web of Science ®Google Scholar
• Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014;32(39):5087–5097.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–2170.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
   PubMed Web of Science ®Google Scholar
• Panatto D, Amicizia D, Bragazzi NL, et al. Human papillomavirus vaccine: State of the art and future perspectives. Adv Protein Chem Struct Biol. 2015;101:231–322.
   PubMed Web of Science ®Google Scholar
• Schellenbacher C, Roden RB, Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res. 2017;231:166–175.
   PubMed Web of Science ®Google Scholar
• Gambhira R, Jagu S, Karanam B, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol. 2007;81(21):11585–11592.
   PubMed Web of Science ®Google Scholar
• Gambhira R, Karanam B, Jagu S, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol. 2007;81(24):13927–13931.
   PubMed Web of Science ®Google Scholar
• De Vuyst H, Lillo F, Broutet N, et al. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17(6):545–554.
   PubMed Web of Science ®Google Scholar
• Hinten F, Meeuwis KA, Van Rossum MM, et al. HPV-related (pre) malignancies of the female anogenital tract in renal transplant recipients. Crit Rev Oncol Hematol. 2012;84(2):161–180.
   PubMed Web of Science ®Google Scholar